Complete Filing Data
CalciMedica, Inc. reported Stockholders Equity of -$6.64 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean CalciMedica, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$29.6M | -$13.7M | -$34.4M | -$7.8M | -$35.8M | -$27.5M | -$37.0M |
| Research And Development Expense | $15.2M | $14.5M | $15.9M | $8.4M | $18.9M | $21.0M | $30.6M |
| Operating Income Loss | -$23.1M | -$24.2M | -$38.1M | -$14.2M | -$35.9M | -$29.8M | -$37.5M |
| Operating Expenses | $23.1M | $24.2M | $38.1M | $14.2M | $35.9M | $29.8M | $37.5M |
| General And Administrative Expense | $7.9M | $9.7M | $22.2M | $5.8M | $17.0M | $8.9M | $6.9M |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | -$4.0K | $2.0K | $2.0K | $0.00 | -$12.0K | -$7.0K | $3.0K |
| Comprehensive Income Net Of Tax | -$29.6M | -$13.7M | -$34.4M | -$9.1M | -$35.8M | -$27.5M | -$37.0M |
| Net Income Loss Available To Common Stockholders Basic | -$29.6M | -$13.7M | -$34.4M | -$9.1M | -$35.8M | -$34.7M | -$44.1M |
| Nonoperating Income Expense | -$6.4M | $10.5M | $3.7M | $6.4M | |||
| Other Nonoperating Income Expense | $268.0K | $0.00 | $550.0K | -$28.0K | |||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$4.0K | $2.0K | $2.0K | ||||
| Non Cash Interest Expense | $0.00 | $110.0K | $132.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$7.8M | -$6.0M | -$5.0M | -$5.6M | -$4.0M | $130.0K | -$4.6M | -$6.3M | -$19.3M | -$2.6M | -$3.0M | -$3.6M | -$8.0M | -$7.7M | -$11.4M | -$4.7M | -$5.9M | -$7.8M | -$10.2M | -$10.3M | -$6.3M |
| Research And Development Expense | $3.9M | $4.1M | $4.2M | $3.5M | $4.2M | $2.9M | $2.8M | $3.8M | $6.5M | $1.2M | $2.3M | $2.9M | $4.0M | $4.2M | $6.4M | $4.8M | $4.6M | $6.1M | $8.4M | ||
| Operating Income Loss | -$5.6M | -$6.6M | -$6.5M | -$5.7M | -$6.5M | -$5.8M | -$4.8M | -$6.6M | -$22.3M | -$3.3M | -$3.6M | -$4.2M | -$8.0M | -$7.7M | -$11.5M | -$6.8M | -$6.0M | -$7.8M | -$10.4M | ||
| Operating Expenses | $5.6M | $6.6M | $6.5M | $5.7M | $6.5M | $5.8M | $4.8M | $6.6M | $22.3M | $3.3M | $3.6M | $4.2M | $8.0M | $7.7M | $11.5M | $6.8M | $6.0M | $7.8M | $10.4M | ||
| General And Administrative Expense | $1.8M | $2.6M | $2.3M | $2.2M | $2.4M | $2.8M | $2.1M | $2.8M | $15.8M | $2.0M | $1.3M | $1.3M | $4.0M | $3.6M | $5.0M | $2.1M | $1.4M | $1.7M | $2.0M | ||
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | $5.0K | -$3.0K | -$5.0K | $13.0K | $8.0K | -$19.0K | $0.00 | $0.00 | $0.00 | $56.0K | -$3.0K | -$160.0K | $6.0K | $4.0K | -$3.0K | $7.0K | |||||
| Comprehensive Income Net Of Tax | -$7.8M | -$6.0M | -$5.0M | -$5.6M | -$3.9M | $111.0K | -$4.6M | -$6.3M | -$19.3M | -$9.8M | -$8.2M | -$10.3M | -$8.0M | -$7.7M | -$11.4M | -$4.7M | -$5.9M | -$7.8M | -$10.2M | ||
| Net Income Loss Available To Common Stockholders Basic | -$7.8M | -$6.0M | -$5.0M | -$5.6M | -$4.0M | $130.0K | -$4.6M | -$6.3M | -$19.3M | -$8.0M | -$7.7M | -$11.4M | -$7.1M | -$9.4M | -$9.1M | -$12.3M | |||||
| Nonoperating Income Expense | -$2.2M | $665.0K | $1.5M | $118.0K | $2.6M | $5.9M | $214.0K | $279.0K | $3.1M | $707.0K | $559.0K | $581.0K | |||||||||
| Other Nonoperating Income Expense | $0.00 | $269.0K | $0.00 | $0.00 | $307.0K | $214.0K | $279.0K | -$116.0K | -$49.0K | -$29.0K | |||||||||||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $5.0K | -$3.0K | -$5.0K | $13.0K | $8.0K | -$19.0K | |||||||||||||||
| Non Cash Interest Expense | $0.00 | $110.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$6.6M | $14.4M | $8.2M | -$71.3M | -$64.0M | $94.8M | -$103.0M | -$66.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $11.5M | $7.9M | $5.5M | $1.5M | $4.8M | $33.4M | $15.9M | $12.8M |
| Retained Earnings Accumulated Deficit | -$189.3M | -$159.8M | -$146.1M | -$111.7M | -$169.2M | -$133.4M | -$105.8M | |
| Prepaid Expense And Other Assets Current | $259.0K | $248.0K | $296.0K | $254.0K | $3.4M | $4.2M | $315.0K | |
| Liabilities Current | $3.8M | $3.7M | $4.0M | $4.8M | $4.1M | $7.0M | $12.3M | |
| Liabilities And Stockholders Equity | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M | $101.8M | $40.7M | |
| Liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M | $7.0M | $12.3M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $3.6M | $2.4M | $4.1M | -$3.3M | -$20.1M | $17.5M | $3.0M | |
| Cash And Cash Equivalents At Carrying Value | $11.5M | $7.9M | $5.5M | $1.3M | $13.4M | $33.4M | $15.9M | |
| Assets Current | $13.5M | $19.7M | $11.6M | $1.7M | $67.1M | $99.2M | $36.3M | |
| Assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M | $101.8M | $40.7M | |
| Additional Paid In Capital Common Stock | $182.7M | $174.2M | $154.2M | $40.4M | $234.2M | $228.2M | $2.9M | |
| Accounts Payable Current | $1.2M | $2.0M | $1.4M | $2.9M | $527.0K | $2.5M | $4.6M | |
| Property Plant And Equipment Net | $50.0K | $119.0K | $167.0K | $147.0K | $2.0M | $1.9M | $2.0M | |
| Common Stock Value | $4.0K | $4.0K | $1.0K | $1.0K | $2.0K | $2.0K | ||
| Short Term Investments | $1.5M | $10.7M | $5.7M | $0.00 | $50.3M | $61.6M | $20.1M | |
| Accretion Amortization Of Discounts And Premiums Investments | $345.0K | $608.0K | $145.0K | $319.0K | -$58.0K | -$1.0K | $68.0K | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $0.00 | $4.0K | $2.0K | -$37.0K | -$16.0K | -$4.0K | $3.0K | |
| Other Liabilities Current | $0.00 | $199.0K | $3.2M | $3.1M | $3.1M | |||
| Other Accrued Liabilities Current | $290.0K | $866.0K | $1.5M | $572.0K | ||||
| Warrant Liability | $8.0M | $1.7M | $0.00 | $2.6M | ||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Other Assets | $11.0K | $10.0K | $413.0K | $1.4M | ||||
| Accrued Clinical Trial Costs | $1.1M | $820.0K | $1.1M | $1.1M | ||||
| Accrued Liabilities Current | $200.0K | $304.0K | $1.4M | $2.3M | ||||
| Prepaid Expense And Other Assets Noncurrent | $29.0K | $608.0K | $2.4M | |||||
| Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger | $0.00 | $29.2M | ||||||
| Operating Lease Right Of Use Asset | $0.00 | $48.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$268.0K | $6.1M | $10.9M | $9.0M | $13.8M | $17.2M | $12.2M | $16.2M | $22.0M | -$71.8M | -$70.0M | -$67.3M | $72.1M | $78.7M | $84.6M | $90.6M | -$116.2M | -$110.5M | -$92.9M | -$83.0M | -$72.9M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $5.5M | $5.9M | $12.6M | $9.2M | $5.1M | $6.8M | $11.6M | $19.1M | $24.4M | $96.0K | $222.0K | $1.1M | $11.5M | $7.9M | $10.6M | $95.0M | $17.5M | $21.2M | $27.0M | |||
| Retained Earnings Accumulated Deficit | -$178.6M | -$170.8M | -$164.8M | -$155.5M | -$149.9M | -$145.9M | -$141.9M | -$137.3M | -$131.0M | -$197.4M | -$187.6M | -$179.3M | -$160.5M | -$152.5M | -$144.8M | -$124.2M | ||||||
| Prepaid Expense And Other Assets Current | $539.0K | $655.0K | $197.0K | $1.1M | $1.3M | $894.0K | $682.0K | $961.0K | $336.0K | $1.1M | $1.0M | $2.9M | $1.9M | $2.5M | $3.1M | $138.0K | ||||||
| Liabilities Current | $3.7M | $3.5M | $4.5M | $3.8M | $3.9M | $4.3M | $3.7M | $4.0M | $12.7M | $3.8M | $4.3M | $4.2M | $4.5M | $4.1M | $6.3M | $7.7M | ||||||
| Liabilities And Stockholders Equity | $14.9M | $19.1M | $25.3M | $16.2M | $21.1M | $27.1M | $15.8M | $20.2M | $34.7M | $45.4M | $54.0M | $60.6M | $76.6M | $82.8M | $90.9M | $98.4M | ||||||
| Liabilities | $15.2M | $13.0M | $14.5M | $7.2M | $7.2M | $9.9M | $3.7M | $4.0M | $12.7M | $3.8M | $4.3M | $4.3M | $4.5M | $4.2M | $6.3M | $7.8M | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $4.6M | $1.2M | $22.9M | -$3.6M | -$22.8M | $5.3M | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | $5.5M | $5.9M | $12.6M | $9.2M | $5.1M | $6.8M | $11.6M | $19.1M | $24.4M | $10.2M | $13.9M | $8.4M | $11.5M | $7.9M | $10.6M | $95.0M | ||||||
| Assets Current | $14.9M | $19.0M | $25.2M | $15.7M | $20.4M | $26.6M | $15.3M | $20.0M | $34.5M | $45.1M | $51.7M | $58.2M | $74.5M | $76.1M | $88.8M | $95.1M | ||||||
| Assets | $14.9M | $19.1M | $25.3M | $16.2M | $21.1M | $27.1M | $15.8M | $20.2M | $34.7M | $45.4M | $54.0M | $60.6M | $76.6M | $82.8M | $90.9M | $98.4M | ||||||
| Additional Paid In Capital Common Stock | $178.3M | $176.9M | $175.7M | $164.5M | $163.7M | $163.2M | $154.1M | $153.5M | $153.0M | $239.1M | $237.4M | $235.8M | $232.6M | $231.2M | $229.4M | $214.8M | ||||||
| Accounts Payable Current | $1.1M | $1.9M | $2.0M | $1.5M | $2.1M | $1.5M | $1.4M | $1.7M | $2.1M | $498.0K | $1.0M | $541.0K | $2.1M | $2.1M | $2.0M | $4.6M | ||||||
| Property Plant And Equipment Net | $49.0K | $105.0K | $118.0K | $130.0K | $138.0K | $153.0K | $187.0K | $199.0K | $134.0K | $1.9M | $1.9M | $2.1M | $2.0M | $2.0M | $1.8M | |||||||
| Common Stock Value | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K | $1.0K | $1.0K | $1.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | ||||||
| Short Term Investments | $8.6M | $12.0M | $12.1M | $5.5M | $14.1M | $19.0M | $2.9M | $9.8M | $33.5M | $36.8M | $46.9M | $61.1M | $65.7M | $75.1M | ||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $106.0K | $163.0K | $2.0K | $17.0K | -$40.0K | $16.0K | ||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $1.0K | -$4.0K | -$1.0K | $4.0K | -$9.0K | -$17.0K | -$123.0K | -$179.0K | -$176.0K | $6.0K | $6.0K | |||||||||||
| Other Liabilities Current | $0.00 | $0.00 | $113.0K | $2.8M | $2.5M | $2.3M | $2.2M | $1.6M | $2.2M | $2.2M | ||||||||||||
| Other Accrued Liabilities Current | $1.0M | $895.0K | $1.2M | $1.1M | $941.0K | $1.8M | $1.4M | $1.1M | $1.5M | |||||||||||||
| Warrant Liability | $2.6M | $1.0M | $1.4M | $3.4M | $3.3M | $5.6M | $0.00 | $0.00 | $0.00 | |||||||||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||
| Other Assets | $11.0K | $11.0K | $11.0K | $396.0K | $472.0K | $377.0K | $385.0K | $1.0K | $27.0K | |||||||||||||
| Accrued Clinical Trial Costs | $1.5M | $670.0K | $1.2M | $1.1M | $829.0K | $1.0M | $860.0K | $1.2M | $1.0M | |||||||||||||
| Accrued Liabilities Current | $200.0K | $463.0K | $1.0M | $264.0K | $396.0K | $2.1M | $1.0M | |||||||||||||||
| Prepaid Expense And Other Assets Noncurrent | $29.0K | $29.0K | $136.0K | $29.0K | $1.5M | |||||||||||||||||
| Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger | $0.00 | $29.2M | ||||||||||||||||||||
| Operating Lease Right Of Use Asset | $0.00 | $0.00 | $10.0K | $290.0K | $384.0K | $476.0K | $600.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Share Based Compensation | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M | $1.8M | $738.0K |
| Net Cash Provided By Used In Operating Activities | -$21.2M | -$21.1M | -$25.7M | -$11.8M | -$31.5M | -$32.1M | -$31.2M |
| Net Cash Provided By Used In Investing Activities | $9.6M | -$4.4M | $8.9M | -$4.0K | $10.8M | -$42.6M | -$20.6M |
| Increase Decrease In Prepaid Expenses And Other Current And Noncurrent Assets | -$536.0K | $228.0K | -$3.0M | $1.5M | -$1.4M | $2.4M | -$1.6M |
| Increase Decrease In Accounts Payable | -$840.0K | $601.0K | -$1.4M | $933.0K | -$2.1M | -$1.5M | $1.4M |
| Net Cash Provided By Used In Financing Activities | $15.2M | $28.0M | $20.9M | $8.5M | $695.0K | $92.2M | $54.9M |
| Payments To Acquire Property Plant And Equipment | $28.0K | $8.0K | $78.0K | $4.0K | $488.0K | $1.0M | $605.0K |
| Proceeds From Sale Maturity And Collections Of Investments | $25.5M | $24.6M | $15.1M | $64.3M | $105.8M | $20.1M | |
| Proceeds From Stock Options Exercised | $25.0K | $20.0K | $0.00 | $695.0K | $77.0K | $134.0K | |
| Payments To Acquire Investments | $15.9M | $29.0M | $6.1M | $35.6M | $94.6M | $61.6M | |
| Proceeds From Issuance Of Common Stock | $8.0K | $27.9M | $10.3M | $96.3M | |||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$319.0K | -$868.0K | -$1.8M | $1.2M | |||
| Increase Decrease In Accrued Liabilities | -$104.0K | -$1.1M | -$977.0K | $640.0K | |||
| Proceeds From Other Equity | $5.5M | $49.0K | $246.0K | $18.0K | |||
| Increase Decrease In Other Operating Liabilities | -$1.9M | $95.0K | $280.0K | $1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $549.0K | $414.0K | $11.1M | $335.0K | $1.1M | $226.0K |
| Net Cash Provided By Used In Operating Activities | -$4.9M | -$4.7M | -$5.4M | -$3.6M | -$9.3M | -$10.7M |
| Net Cash Provided By Used In Investing Activities | -$1.2M | -$13.1M | $4.8M | -$4.0K | -$13.7M | $16.9M |
| Increase Decrease In Prepaid Expenses And Other Current And Noncurrent Assets | -$403.0K | $537.0K | -$129.0K | -$66.0K | -$1.7M | -$201.0K |
| Increase Decrease In Accounts Payable | -$87.0K | $129.0K | -$1.0M | -$657.0K | -$508.0K | -$380.0K |
| Net Cash Provided By Used In Financing Activities | $10.7M | $19.0M | $23.5M | $1.0K | $92.0K | -$840.0K |
| Payments To Acquire Property Plant And Equipment | $9.0K | $0.00 | $4.0K | $136.0K | $147.0K | |
| Proceeds From Sale Maturity And Collections Of Investments | $5.4M | $4.8M | $4.8M | $14.0M | $8.0M | |
| Proceeds From Stock Options Exercised | $1.0K | $92.0K | $11.0K | |||
| Payments To Acquire Investments | $6.6M | $17.9M | $0.00 | $10.8M | $21.5M | |
| Proceeds From Issuance Of Common Stock | $8.0K | $19.0M | $10.3M | |||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $756.0K | $111.0K | $6.8M | $828.0K | ||
| Increase Decrease In Accrued Liabilities | $489.0K | $741.0K | -$1.4M | |||
| Proceeds From Other Equity | $968.0K | $0.00 | ||||
| Increase Decrease In Other Operating Liabilities | -$1.2M | -$989.0K | -$1.7M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.97 | -$1.22 | -$7.66 | -$111.16 | -$1.69 | -$5.25 | -$33.41 |
| Weighted Average Number Of Shares Outstanding Basic | 15.0M | 11.2M | 4.5M | 82.2K | 21.2M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 15.0M | 11.2M | 4.5M | 82.2K | 21.2M | ||
| Earnings Per Share Basic | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-1.69 | ||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 0.00 | 10.0M | 10.0M | 10.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 15.4M | 13.5M | 5.8M | 84.2K | 21.4M | 21.0M | 1.4M |
| Common Stock Shares Issued | 15.4M | 13.5M | 5.8M | 84.2K | 21.4M | 21.0M | 1.4M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 5.7M | 500.0M | 500.0M | 188.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 21.2M | 6.6M | 1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.52 | -$0.40 | -$0.36 | -$0.50 | -$0.36 | $0.01 | -$0.82 | -$1.11 | -$23.43 | -$31.04 | -$36.55 | -$46.13 | -$0.38 | -$0.36 | -$0.54 | -$2.52 | -$6.79 | -$6.61 | -$9.30 |
| Weighted Average Number Of Shares Outstanding Basic | 15.1M | 15.0M | 14.1M | 11.1M | 11.1M | 9.8M | 5.7M | 5.7M | 823.1K | 83.2K | 82.9K | 78.7K | 21.3M | 21.1M | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 15.1M | 15.0M | 14.1M | 11.1M | 11.1M | 10.0M | 5.7M | 5.7M | 823.1K | 83.2K | 82.9K | 78.7K | 21.3M | 21.1M | |||||
| Earnings Per Share Basic | $-0.52 | $-0.40 | $-0.36 | $-0.50 | $-0.36 | $0.01 | $-0.82 | $-1.11 | $-23.43 | $-31.04 | $-36.55 | $-46.13 | $-0.38 | $-0.36 | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Common Stock Shares Outstanding | 14.3M | 14.0M | 14.0M | 10.8M | 10.8M | 10.7M | 5.7M | 5.7M | 5.7M | ||||||||||
| Common Stock Shares Issued | 14.3M | 14.0M | 14.0M | 10.8M | 10.8M | 10.7M | 5.7M | 5.7M | 5.7M | ||||||||||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | ||||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 21.4M | 21.3M | 21.1M | 21.0M | 2.8M | 1.4M | 1.4M | 1.3M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M | $1.8M | $738.0K |
| Stock Issued During Period Value Stock Options Exercised | $25.0K | $20.0K | $18.0K | $695.0K | $77.0K | $134.0K | |
| Depreciation | $46.0K | $58.0K | $58.0K | $338.0K | $519.0K | $395.0K | $303.0K |
| Changes In Fair Value Of Financial Instruments | -$6.0M | $9.5M | $3.2M | ||||
| Investment Income Interest | $575.0K | $126.0K | $143.0K | $393.0K | |||
| Fair Value Adjustment Of Warrants | $5.2M | -$9.5M | -$1.1M | -$3.8M | |||
| Transaction Costs Assoicated With Warrants | $0.00 | $776.0K | $0.00 | ||||
| Stock Issued During Period Value New Issues | $5.5M | $49.0K | $246.0K | ||||
| Issuance Of Common Shares From Private Placement Net | 7.9M | 10.3M | |||||
| Conversion Of Stock Amount Issued1 | $0.00 | $62.1M | $131.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $626.0K | $1.2M | $549.0K | $781.0K | $486.0K | $414.0K | $482.0K | $463.0K | $11.1M | $757.0K | $321.0K | $335.0K | $1.4M | $1.3M | $1.1M | $561.0K | $214.0K | $226.0K | $250.0K | $142.0K | $156.0K |
| Stock Issued During Period Value Stock Options Exercised | $25.0K | $16.0K | $4.0K | $8.0K | $17.0K | $1.0K | $27.0K | $495.0K | $92.0K | $54.0K | $12.0K | $11.0K | $122.0K | $9.0K | |||||||
| Depreciation | $15.0K | $15.0K | $15.0K | $15.0K | $12.0K | $14.0K | $13.0K | $122.0K | $118.0K | $93.0K | |||||||||||
| Changes In Fair Value Of Financial Instruments | -$2.0M | $500.0K | $1.7M | -$100.0K | $2.3M | $5.6M | $0.00 | $0.00 | $3.2M | $756.0K | $588.0K | $581.0K | |||||||||
| Investment Income Interest | $171.0K | $60.0K | $35.0K | $28.0K | $33.0K | $39.0K | $3.0K | $9.0K | $108.0K | $160.0K | |||||||||||
| Fair Value Adjustment Of Warrants | -$1.4M | -$5.6M | -$1.1M | -$581.0K | |||||||||||||||||
| Transaction Costs Assoicated With Warrants | $0.00 | $776.0K | $0.00 | ||||||||||||||||||
| Stock Issued During Period Value New Issues | $777.0K | $968.0K | $47.0K | $72.0K | $79.5M | ||||||||||||||||
| Issuance Of Common Shares From Private Placement Net | 7.9M | 10.3M | |||||||||||||||||||
| Conversion Of Stock Amount Issued1 | $0.00 | $62.1M |
Most recent annual filing with the SEC: March 3, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.